Category: Pharma, Life Sciences & Med Tech Players
-
Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca
The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyeth’s cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.
-
UPC Munich LD revokes Promosome’s mRNA patent, dismisses infringement claims against BioNTech, Pfizer over Comirnaty
The UPC’s Munich LD revoked Promosome’s mRNA patent as invalid over prior art and found no infringement by BioNTech and Pfizer’s Comirnaty vaccine, ending the dispute.
-
UPC CoA rejects Guardant’s provisional measures appeal against Sophia Genetics on urgency grounds; reverses added matter finding
The UPC’s CoA has dismissed Guardant Health’s provisional measures appeal over a cancer-detection patent against Sophia Genetics, finding an unexplained three-month gap fatal to urgency, though it reversed the added matter ruling below.
-
Federal Circuit applies Third Circuit law to vacate District of Delaware’s waiver of preliminary injunction bond
The district court made the rare decision to waive Otsuka Pharmaceutical’s requirement to post a bond after granting it a preliminary injunction against Hetero Labs’ generic competitor.
-
FTC urges Fourth Circuit to reverse summary judgment for Johnson & Johnson in Stelara antitrust suit: ‘specific intent not required to prove monopolization’
The U.S. Federal Trade Commission has told the Fourth Circuit that a Virginia court wrongly required proof of specific intent before CareFirst’s Stelara biosimilar-patent monopoly claims against Johnson & Johnson could proceed.
-
Federal Circuit affirms invalidation of Enanta’s Paxlovid-related patent: finds “typo” defense insufficient to fix written description gap in provisional filing
The United States Court of Appeals for the Federal Circuit has affirmed the invalidation of Enanta’s Paxlovid-related patent, rejecting its bid to blame a one-carbon typo in its provisional filing, and leaving Pfizer’s earlier disclosure now free to anticipate the claims.
-
Amgen must pay $20.2 million in damages over antibody patent infringement: District of Delaware jury
Following a trial in the United States District Court for the District of Delaware last week, a jury has found that Amgen’s subsidiary Teneobio has infringed one of competitor Harbour Antibodies’s antibody-related patents and owes over $20 million in damages.
-
Boston Scientific raises University of Texas’s alleged inflammatory comments, A-Rod comparisons in appeal of $42M District of Delaware jury verdict
Counsel compared an expert witness to the disgraced baseball player, while also suggesting that the standard for finding invalidity should be similar to deciding whether to commit someone to a psychiatric institution.
-
Incyte acquires bleeding-disorder biotech Vega Therapeutics as Jakafi patent cliff looms
Incyte will pay $1.25 billion upfront for Vega Therapeutics, with up to $750 million more in sales milestones. The $2.4 billion-a-year drug loses U.S. exclusivity in December 2028 after a pediatric extension.
-
Podcast: marking UPC’s three-year anniversary with UPC litigator Dr. Wim Maas (Winston Taylor)
In our latest podcast episode, ip fray interviewed Wim Maas, partner and trial attorney at Winston Taylor, who is a very frequent user of the Unified Patent Court.